This research trial studies phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutation analysis in tissue samples from older patients with stage I breast cancer. Studying samples of tissue from patients with stage I breast cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.
PRIMARY OBJECTIVES: To assess the relapse free-survival difference between patients with PIK3CA mutated and wild-type (WT) tumors and therefore validate PIK3CA mutation status as an important biomarker in women 70 years or older diagnosed with breast cancer. OUTLINE: Previously collected tissue samples are analyzed via mutation analysis of PIK3CA.
Study Type
OBSERVATIONAL
Enrollment
505
Correlative sciences
Breast cancer-free interval for patients with PIK3CA-mutated tumors
Time frame: baseline
Tumor size
Time frame: baseline
Estrogen receptor status
Time frame: baseline
Lymph node status
Time frame: baseline
Treatment group associated with PIK3CA expression
Time frame: baseline
Overall survival associated with PIK3CA
Time frame: baseline
Breast cancer specific survival associated with PIK3CA expression
Time frame: baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.